Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 4-5x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Wednesdays: CRISPR Corner: Monthly gene editing news
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Sundays: Building Biotech: Strategic Topics
In addition we aim to put out 1-2 podcasts episodes per week. One on Tue/Wed focusing on interesting industry related content and a second on Fri/Sat which will likely be more of a news recap.
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
Today we discuss the current state of venture capital-backed startups in the United States, highlighting the challenges they face in achieving success. Data from Carta shows that while over half of startups founded in 2019 are still operational, historical venture returns indicate that only a small percentage of these companies will ultimately thrive. The data reveals that most startups either fail outright or generate minimal returns for investors, and even those that reach Series A funding still face long odds of achieving significant exits. VCs often prioritize aggressive growth strategies, seeking massive valuations, which can lead to unsustainable practices and ultimately result in closure. We explore an alternative strategic framework where VCs might consider more realistic growth targets and aim for smaller but more attainable outcomes.
📣🎙️ TODAY’S POCAST:
[0:00] Intro
[0:45] 55% of startups are still around after 5 years
[1:15] 65% of companies wind up with <1x return
[2:30] 16% of start ups go on to secure Series A
[3:30] 4% of IPOs go on to IPO or be acquired within 5 years
[4:40] 11-12 years is the average from startup to IPO
[5:15] Strategies for building sustainable companies
[6:50] Conclusion
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
The Venture Mirage: Why Surviving Isn’t Thriving in Startup Land